SynthesisNeurosurgical review2026
Salvage stereotactic radiosurgery following primary microsurgical resection for vestibular schwannomas: A systematic review & meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic radiosurgery (SRS) is a commonly utilized modality for the treatment of vestibular schwannomas (VS), either as upfront treatment or after initial microsurgery. The aim of this study was to assess outcomes in patients with VSs who underwent salvage SRS for tumor progression or residual tumor following primary microsurgical resection. The MEDLINE/PubMed database was queried from inception to November 2024. The primary outcomes of interest were the VS-related reoperation and repeat SRS following salvage SRS. The secondary outcomes were radiological tumor control rates, post-SRS facial nerve function, and new or worsened clinical symptoms. Eleven studies were eligible for this review, containing 553 patients who underwent salvage SRS following initial microsurgical resection. During the follow-up period, 5.2% (95%CI 3.4–7.8) and 3.2% (95%CI 1.9–5.6) of all patients who underwent salvage SRS required repeat microsurgery and SRS, respectively. Radiological tumor control was 87.5% (95%CI 76.6–93.7), with volumetric reduction recorded at 65.6% (95%CI 50.4–78.2). Facial nerve function worsened in 7.8% (95%CI 4.7–12.7) of patients, and 5.6% (95%CI 3.4–9) developed new or worsened trigeminal neuropathy. 3.3% (95%CI 1.4–7.7) and 3.4% (95%CI 1.8–6.3) of patients reported new or worsening tinnitus and vertigo, respectively. This study shows that salvage SRS for treating VS after failed microsurgery yielded favorable tumor control with reasonable complication rates, including low rates of cranial nerve deterioration. SRS proved to be a viable salvage treatment option for VS in case of tumor recurrence or progression after initial microsurgery, particularly for patients who are not candidates for repeat surgery or prefer a less invasive approach. These results may inform patient counseling and clinical decision-making following failed microsurgical resection of VS.
Indexed as
Identifiers
41840066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.